Anti-HER2/neu Immunocytokine, IgG (L19)-GM-CSF (ACFP-SH047)
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-HER2/neu IgG to GM-CSF. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the HER2/neu as well as the biological activity of GM-CSF. Pharmacokinetic studies showed that anti-HER2/neu IgG3-(GM-CSF) is stable in the blood. In addition, anti-HER2/neu IgG3-(GM-CSF) was able to target the HER2/neu-expressing tumor and enhance the immune response against the targeted Ag HER2/neu. Anti-HER2/neu IgG3-(GM-CSF) is able to enhance both Th1-and Th2-mediated immune responses. This immunocytokine was designed for treating HER-2/neu over-expressing cancer.
Specifications
- Target
- HER2/neu
- Molecule Class
- IgG3-GM-CSF
- Species Reactivity
- Human
- Host
- Human
- Expression Host
- CHO
- Clone
- L19
- Related Disease
- HER-2/neu over-expressing cancer
- Cytokines 1
- GM-CSF
- Cytokines 1 Description
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as colony stimulating factor 2 (CSF2), is a monomeric glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts that functions as a cytokine. The pharmaceutical analogs of naturally occurring GM-CSF are called sargramostim and molgramostim.
- Cytokine 1 Species
- Human
- Applications
- This product can be used therapeutically to deliver biologically active ligands to a desired tissue.
Target
- Alternative Names
- ERBB2; erb-b2 receptor tyrosine kinase 2; NEU; NGL; HER2; TKR1; CD340; HER-2
- Entrez Gene ID
- 2064
- UniProt ID
- P04626
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: